DR. DATASONS LABS LTD.

NSE : NABSE : 533412ISIN CODE : INE928K01013Industry : Pharmaceuticals & DrugsHouse : Private
BSE6.290 (0 %)
PREV CLOSE ( ) 6.29
OPEN PRICE ( ) 6.29
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 6.29 (1397430)
VOLUME 802500
TODAY'S LOW / HIGH ( )6.29 6.29
52 WK LOW / HIGH ( ) 6.296.29
NSE
This Company is not listed in NSE
( in Million)
Select year
ParticularsMar2014Mar2013Mar2012
Profit Before Tax10.9426.48NA
Adjustment634.501074.46NA
Changes In working Capital699.53-705.02NA
Cash Flow after changes in Working Capital1344.97395.92NA
Cash Flow from Operating Activities1344.81379.26NA
Cash Flow from Investing Activities-2255.64-343.97NA
Cash Flow from Financing Activities-1199.782045.34NA
Net Cash Inflow / Outflow-2110.622080.63NA
Opening Cash & Cash Equivalents2125.4744.84NA
Cash & Cash Equivalent on Amalgamation / Take over / MergerNANANA
Cash & Cash Equivalent of Subsidiaries under liquidationsNANANA
Translation adjustment on reserves / op cash balalces frgn subsidiariesNANANA
Effect of Foreign Exchange FluctuationsNANANA
Closing Cash & Cash Equivalent14.852125.47NA

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.